AL-794 not checked

Alios Biopharma Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“AL-794 will be administered as tablets orally on Day 1 to Day 5.”In the company’s words, NCT03411421 on ClinicalTrials.gov
Tested for
Influenza in Humans
Main trialPhase 1
“This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy volunteers.”In the company’s words, NCT02888327 on ClinicalTrials.gov

Other drugs for Influenza in Humans

All 30 drugs for Influenza in Humans

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Completed 30 May 2017 A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
Phase 1Terminated 27 Apr 2018 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AL-794

Following is part of Solo: you see every change to AL-794 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in